CML - Not only BCR-ABL1 matters
Publication date: Available online 7 June 2020Source: Best Practice & Research Clinical HaematologyAuthor(s): Jenny Rinke, Andreas Hochhaus, Thomas Ernst (Source: Best Practice and Research Clinical Haematology)
Source: Best Practice and Research Clinical Haematology - June 8, 2020 Category: Hematology Source Type: research

Acute myeloid leukemia and artificial intelligence, algorithms and new scores
Publication date: Available online 7 June 2020Source: Best Practice & Research Clinical HaematologyAuthor(s): Nathan Radakovich, Matthew Cortese, Aziz Nazha (Source: Best Practice and Research Clinical Haematology)
Source: Best Practice and Research Clinical Haematology - June 8, 2020 Category: Hematology Source Type: research

Molecular markers in ALL: Clinical implications
Publication date: Available online 7 June 2020Source: Best Practice & Research Clinical HaematologyAuthor(s): Shunsuke Kimura, Charles G. Mullighan (Source: Best Practice and Research Clinical Haematology)
Source: Best Practice and Research Clinical Haematology - June 8, 2020 Category: Hematology Source Type: research

Myeloid neoplasms with germline predisposition: Practical considerations and complications in the search for new susceptibility loci
Publication date: Available online 8 June 2020Source: Best Practice & Research Clinical HaematologyAuthor(s): Hetty Carraway, Thomas LaFramboise (Source: Best Practice and Research Clinical Haematology)
Source: Best Practice and Research Clinical Haematology - June 8, 2020 Category: Hematology Source Type: research

Founder and subclonal mutations in myelodysplastic syndromes and related myeloid neoplasms
Publication date: Available online 5 June 2020Source: Best Practice & Research Clinical HaematologyAuthor(s): Hideki Makishima (Source: Best Practice and Research Clinical Haematology)
Source: Best Practice and Research Clinical Haematology - June 6, 2020 Category: Hematology Source Type: research

WGS and WTS in leukaemia: A tool for diagnostics?
Publication date: Available online 5 June 2020Source: Best Practice & Research Clinical HaematologyAuthor(s): Manja Meggendorfer, Wencke Walter, Torsten Haferlach (Source: Best Practice and Research Clinical Haematology)
Source: Best Practice and Research Clinical Haematology - June 6, 2020 Category: Hematology Source Type: research

Cytogenetics in the genomic era
Publication date: Available online 4 June 2020Source: Best Practice & Research Clinical HaematologyAuthor(s): Isabel Granada, Laura Palomo, Neus Ruiz, Mar Mallo, Francesc Solé (Source: Best Practice and Research Clinical Haematology)
Source: Best Practice and Research Clinical Haematology - June 5, 2020 Category: Hematology Source Type: research

Editorial Board / Aims & Scope
Publication date: June 2020Source: Best Practice & Research Clinical Haematology, Volume 33, Issue 2Author(s): (Source: Best Practice and Research Clinical Haematology)
Source: Best Practice and Research Clinical Haematology - May 24, 2020 Category: Hematology Source Type: research

Index
Publication date: June 2020Source: Best Practice & Research Clinical Haematology, Volume 33, Issue 2Author(s): (Source: Best Practice and Research Clinical Haematology)
Source: Best Practice and Research Clinical Haematology - May 24, 2020 Category: Hematology Source Type: research

Establishing specific response criteria for MDS/MPN - Getting closer to reality?
Publication date: Available online 7 May 2020Source: Best Practice & Research Clinical HaematologyAuthor(s): Matthew T. Villaume, Michael R. Savona (Source: Best Practice and Research Clinical Haematology)
Source: Best Practice and Research Clinical Haematology - May 7, 2020 Category: Hematology Source Type: research

Juvenile myelomonocytic leukemia – A bona fide RASopathy syndrome
Publication date: Available online 29 April 2020Source: Best Practice & Research Clinical HaematologyAuthor(s): Terra Lasho, Mrinal M. Patnaik (Source: Best Practice and Research Clinical Haematology)
Source: Best Practice and Research Clinical Haematology - April 29, 2020 Category: Hematology Source Type: research

Editorial Board / Aims & Scope
Publication date: March 2020Source: Best Practice & Research Clinical Haematology, Volume 33, Issue 1Author(s): (Source: Best Practice and Research Clinical Haematology)
Source: Best Practice and Research Clinical Haematology - March 3, 2020 Category: Hematology Source Type: research

Index
Publication date: March 2020Source: Best Practice & Research Clinical Haematology, Volume 33, Issue 1Author(s): (Source: Best Practice and Research Clinical Haematology)
Source: Best Practice and Research Clinical Haematology - March 3, 2020 Category: Hematology Source Type: research

Measurable disease evaluation in patients with myeloma
Publication date: Available online 4 February 2020Source: Best Practice & Research Clinical HaematologyAuthor(s): Mikhail RoshalAbstractRecent years saw significant breakthroughs in treatment of multiple myeloma. Durable remissions are now seen in a significant proportion of patients with the previously uniformly incurable and progressive disease. Yet because of deep suppression of the neoplastic myeloma clones by the newer therapies, older disease monitoring techniques are insufficient to distinguish between the patients at high risk of imminent relapse and those in whom durable remission is expected. This review brie...
Source: Best Practice and Research Clinical Haematology - February 5, 2020 Category: Hematology Source Type: research

Multiple Myeloma: Current Advances and Future Directions
Publication date: Available online 5 February 2020Source: Best Practice & Research Clinical HaematologyAuthor(s): Ola Landgren (Source: Best Practice and Research Clinical Haematology)
Source: Best Practice and Research Clinical Haematology - February 5, 2020 Category: Hematology Source Type: research

Genomic profiling of multiple myeloma: new insights and modern technologies
Publication date: Available online 27 January 2020Source: Best Practice & Research Clinical HaematologyAuthor(s): Malin Hultcrantz, Venkata Yellapantula, Even H. RustadAbstractAdvances in technologies for genomic profiling, primarily with next generation sequencing, have lead to a better understanding of the complex genomic landscape in multiple myeloma. Integrated analysis of whole genome, exome and transcriptome sequencing has lead to new insights on disease drivers including translocations, copy number alterations, somatic mutations, and altered gene expression. Disease progression in multiple myeloma is largely dri...
Source: Best Practice and Research Clinical Haematology - January 28, 2020 Category: Hematology Source Type: research

High-risk smoldering myeloma versus early detection of multiple myeloma: current models, goals of therapy, and clinical implications
Publication date: Available online 25 January 2020Source: Best Practice & Research Clinical HaematologyAuthor(s): Chutima Kunacheewa, Elisabet E. ManasanchAbstractMultiple myeloma, a bone marrow cancer, is preceded by precursor stages called monoclonal gammopathy of unknown significance and smoldering multiple myeloma. Over the past few years, highly effective and safe therapies have been made available to treat multiple myeloma. This represents a major breakthrough and has major therapeutic implications. Treatment for multiple myeloma has evolved to include treatment of precursor stages (early treatment) as these ther...
Source: Best Practice and Research Clinical Haematology - January 25, 2020 Category: Hematology Source Type: research

Modern treatments and future directions for newly diagnosed multiple myeloma patients
Publication date: Available online 23 January 2020Source: Best Practice & Research Clinical HaematologyAuthor(s): Sydney Lu, Assistant Attending, Myeloma ServiceAbstractOver the course of the past decade-plus, the therapy of newly diagnosed multiple myeloma has seen incredible advances in the domains of diagnostic evaluation, active medical therapy, and response evaluation. This manuscript reviews the evaluation and management of newly diagnosed active multiple myeloma, with a focus on major clinical trials and IMWG recommendations. The paper describes a current approach for the initial evaluation and workup of a patie...
Source: Best Practice and Research Clinical Haematology - January 24, 2020 Category: Hematology Source Type: research

The changing role of high dose melphalan with stem cell rescue in the treatment of newly diagnosed multiple myeloma in the era of modern therapies—back to the future!
Publication date: Available online 17 January 2020Source: Best Practice & Research Clinical HaematologyAuthor(s): Dickran Kazandjian, Alexander Dew, Elizabeth HillAbstractState of the art treatment for myeloma involves using 3-drug combinations incorporating immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). Clinical trials for 4-drug combinations incorporating monoclonal antibodies added to IMiD and PI based backbones are underway. Recent retrospective analyses show that patients who attain MRD negativity have similar long term outcomes regardless of early or delayed high dose melphalan with autologous st...
Source: Best Practice and Research Clinical Haematology - January 18, 2020 Category: Hematology Source Type: research

Monitoring minimal residual disease in the bone marrow using next generation sequencing
Publication date: Available online 17 January 2020Source: Best Practice & Research Clinical HaematologyAuthor(s): Even H. Rustad, Eileen M. BoyleAbstractAchieving minimal residual disease (MRD) negativity in the bone marrow is one of the strongest prognostic factors in multiple myeloma. Consequently, MRD testing is routinely performed in clinical trials and moving towards standard of care. This review focuses on the role of next generation sequencing (NGS) of tumor-specific immunoglobulin V(D)J sequences for MRD tracking. The immunoglobulin variable regions are ideal targets for tracking, because every tumor cell share...
Source: Best Practice and Research Clinical Haematology - January 18, 2020 Category: Hematology Source Type: research

MDS/MPN-RS-T justified Inclusion as a unique disease entity?
Publication date: Available online 17 January 2020Source: Best Practice & Research Clinical HaematologyAuthor(s): Guillermo Montalban-Bravo, Guillermo Garcia-ManeroABSTRACTMyelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) is a disease entity characterized by anemia, bone marrow dysplasia with ring sideroblasts and persistent thrombocytosis ≥450 x109/L with proliferation of large and morphologically atypical megakaryocytes. Although initially recognized by the World Health Organization only as a provisional entity, next generation sequencing has identified r...
Source: Best Practice and Research Clinical Haematology - January 18, 2020 Category: Hematology Source Type: research

Current and Potential Applications of Positron Emission Tomography for Multiple Myeloma and Plasma Cell Disorders
Publication date: Available online 17 January 2020Source: Best Practice & Research Clinical HaematologyAuthor(s): Gary A. Ulaner, C. Ola LandgrenAbstractFluorine-18 (18F)-fluorodeoxyglucose (FDG) positron emission tomography (PET) allows evaluation of elevated glucose metabolism in malignancies. There has been increasing interest in FDG PET/CT for plasma cell disorders since the International Myeloma Working Group outlined multiple applications of this imaging modality, including distinguishing smoldering myeloma from active multiple myeloma, confirmation of solitary plasmacytoma, and multiple indications in patients w...
Source: Best Practice and Research Clinical Haematology - January 18, 2020 Category: Hematology Source Type: research

Maintenance therapy and need for cessation studies in multiple myeloma: Focus on the future
Publication date: Available online 11 January 2020Source: Best Practice & Research Clinical HaematologyAuthor(s): Benjamin Diamond, Kylee Maclachlan, David J. Chung, Alexander Lesokhin, C. Ola LandgrenAbstractWith ten years of follow-up since the advent of the modern paradigm of combination induction therapy, consolidative autologous stem-cell transplant, and lenalidomide maintenance, median survival for multiple myeloma has increased to almost 50% at 10 years. Given this outlook, the overarching goal of maintenance therapy is to spare patients from the toxicities of aggressive or otherwise intrusive therapies while id...
Source: Best Practice and Research Clinical Haematology - January 15, 2020 Category: Hematology Source Type: research

Tracking myeloma tumor DNA in peripheral blood
Publication date: Available online 14 January 2020Source: Best Practice & Research Clinical HaematologyAuthor(s): Johannes M. Waldschmidt, Tushara Vijaykumar, Birgit Knoechel, Jens G. LohrAbstractOver the past years, the emergence of liquid biopsy technologies has dramatically expanded our ability to assess multiple myeloma without the need for invasive sampling. Interrogation of cell-free DNA from the peripheral blood recapitulates the mutational landscape at excellent concordance with matching bone marrow aspirates. It can quantify disease burden and identify previously undetected resistance mechanisms which may info...
Source: Best Practice and Research Clinical Haematology - January 15, 2020 Category: Hematology Source Type: research

CAR T and CAR NK cells in multiple myeloma: expanding the targets
Publication date: Available online 13 January 2020Source: Best Practice & Research Clinical HaematologyAuthor(s): Urvi A. Shah, Sham MailankodyAbstractMultiple myeloma (MM) is a haematologic malignancy with significant improvements in the overall survival over the last decade. However, patients still relapse and die due to a lack of treatment options. Ultimately, novel therapies with the potential for long term remissions are needed for patients with advanced MM. Research efforts for such immune therapies were not successful until recently when the first immunotherapies for MM were approved in 2015 and many more are un...
Source: Best Practice and Research Clinical Haematology - January 14, 2020 Category: Hematology Source Type: research

Monoclonal Antibodies in Multiple Myeloma: Current and Emerging Targets and Mechanisms of Action
Publication date: Available online 11 January 2020Source: Best Practice & Research Clinical HaematologyAuthor(s): Kitsada Wudhikarn, Beatriz Wills, Alexander M. LesokhinAbstractThe recent development of monoclonal antibodies (mAbs) has revolutionized the treatment armamentarium for multiple myeloma. The success of daratumumab and elotuzumab in relapsed/refractory patients, has generated tremendous enthusiasm for mAbs in this disease. Combination treatment with other anti-MM treatment modalities and clinical evaluation in newly diagnosed patients are expected to fundamentally change the natural history of the disease. A...
Source: Best Practice and Research Clinical Haematology - January 12, 2020 Category: Hematology Source Type: research

Second malignancies in multiple myeloma; emerging patterns and future directions
Publication date: Available online 11 January 2020Source: Best Practice & Research Clinical HaematologyAuthor(s): Kylee Maclachlan, Benjamin Diamond, Francesco Maura, Jens Hillengass, Ingemar Turesson, C. Ola Landgren, Dickran KazandjianAbstractThe changing landscape of treatment options for multiple myeloma has led to a higher proportion of patients achieving deep, long-lasting responses to therapy. With the associated improvement in overall survival, the development of subsequent second malignancies has become of increased significance. The risk of second malignancy after multiple myeloma is affected by a combination...
Source: Best Practice and Research Clinical Haematology - January 12, 2020 Category: Hematology Source Type: research

Tracking of low disease burden in multiple myeloma: using mass spectrometry assays in peripheral blood
Publication date: Available online 11 January 2020Source: Best Practice & Research Clinical HaematologyAuthor(s): Jessica R. Chapman, Katie L. ThorenAbstractEfforts over the last 5 years have demonstrated that it is technically feasible to detect low levels of monoclonal proteins in peripheral blood using mass spectrometry. These methods are based on the fact that an M-protein has a specific amino acid sequence, and therefore, a specific mass. This mass can be tracked over time and can serve as a surrogate marker of the presence of clonal plasma cells. This review describes the use of mass spectrometry to detect M-prot...
Source: Best Practice and Research Clinical Haematology - January 12, 2020 Category: Hematology Source Type: research

“Maintenance therapy and need for cessation studies in multiple myeloma: focus on the future”
Publication date: Available online 11 January 2020Source: Best Practice & Research Clinical HaematologyAuthor(s): Benjamin Diamond, Kylee Maclachlan, David J. Chung, Alexander Lesokhin, C. Ola LandgrenAbstractWith ten years of follow-up since the advent of the modern paradigm of combination induction therapy, consolidative autologous stem-cell transplant, and lenalidomide maintenance, median survival for multiple myeloma has increased to almost 50% at 10 years. Given this outlook, the overarching goal of maintenance therapy is to spare patients from the toxicities of aggressive or otherwise intrusive therapies while id...
Source: Best Practice and Research Clinical Haematology - January 12, 2020 Category: Hematology Source Type: research

Reconstructing the evolutionary history of multiple myeloma
Publication date: Available online 11 January 2020Source: Best Practice & Research Clinical HaematologyAuthor(s): Francesco Maura, Even H. Rustad, Eileen M. Boyle, Gareth J. MorganABSTRACTMultiple myeloma is the second most common lymphoproliferative disorders, characterized by aberrant expansion of monoclonal plasma cells. In the last years, thanks to novel next generation sequencing technologies, multiple myeloma has emerged as one of the most complex hematological cancers, shaped over time by the activity of multiple mutational processes and by the acquisition of key driver events. In this review, we describe how wh...
Source: Best Practice and Research Clinical Haematology - January 11, 2020 Category: Hematology Source Type: research

Contemporary treatment approaches to CMML – is allogeneic HCT the only cure?
Publication date: Available online 30 December 2019Source: Best Practice & Research Clinical HaematologyAuthor(s): Marie Robin, Raphael ItzyksonAbstractChronic Myelomonocytic Leukemias are frequently diagnosed in older adults. Their prognosis is heterogeneous, but several prognostic factors can identify patients with an expected survival of a few years only, including among younger patients eligible for allogeneic stem cell transplantation.Based on the retrospective data available, we discuss how to identify CMML patients for whom curative therapy must be envisaged. We emphasize that, although transplantation remains t...
Source: Best Practice and Research Clinical Haematology - December 30, 2019 Category: Hematology Source Type: research

Myelodysplastic/myeloproliferative neoplasms: are morphology and immunophenotyping still relevant?
Publication date: Available online 26 December 2019Source: Best Practice & Research Clinical HaematologyAuthor(s): V.F.I. Sangiorgio, A. Orazi, D.A. ArberABSTRACTThe term myelodysplastic/myeloproliferative neoplasm (MDS/MPN) refers to a group of clonal hematopoietic neoplasms with overlapping clinical, morphologic and genetic myelodysplastic and myeloproliferative features observed at the time of first presentation. Impaired hematopoiesis morphologically associated with evidence of myelodysplasia manifests clinically with cytopenia/s. Simultaneously, myeloproliferation is seen within the bone marrow and leads to cytosi...
Source: Best Practice and Research Clinical Haematology - December 27, 2019 Category: Hematology Source Type: research

Atypical CML- the role of morphology and precision genomics
Publication date: Available online 6 December 2019Source: Best Practice & Research Clinical HaematologyAuthor(s): Terra LashoAbstractAtypical chronic myeloid leukemia is an esoteric myeloid malignancy with features of both myeloproliferative and myelodysplastic syndromes. This disease is characterized primarily by morphologic-based criteria, and has clinical and molecular features overlapping with other myeloid malignancies. No one molecular abnormality is specific, and multiple mutations are often present in various combinations, due to the malignant multi-step clonal evolution of myeloid malignancies. In this review,...
Source: Best Practice and Research Clinical Haematology - December 19, 2019 Category: Hematology Source Type: research

Autoimmune disease in CMML-the chicken or the egg?
Publication date: Available online 17 December 2019Source: Best Practice & Research Clinical HaematologyAuthor(s): Alexander J. Ambinder, John Miller, Amy E. DeZernABSTRACTChronic myelomonocytic leukemia (CMML) is a clonal disorder that is associated with a wide range of systemic inflammatory and autoimmune diseases (SIADs). Approximately 20% of patients with CMML will have an associated SIAD and recognizing this association is critical to the evaluation, prognostication and management of patients with CMML. In this paper, we review the evidence supporting a causative link between these two entities as well as the dire...
Source: Best Practice and Research Clinical Haematology - December 18, 2019 Category: Hematology Source Type: research

Oligo-monocytic CMML and other pre-CMML states: Clinical impact, prognostication and management
Publication date: Available online 15 December 2019Source: Best Practice & Research Clinical HaematologyAuthor(s): Peter ValentAbstractChronic myelomonocytic leukemia (CMML) is defined by myelodysplasia, pathologic accumulation of monocytes and a substantial risk to transform to secondary acute myeloid leukemia (sAML). In recent years, minimal diagnostic criteria for classical CMML and CMML-variants were proposed. Moreover, potential pre-stages of CMML and interface conditions have been postulated. Oligomonocytic CMML is a condition where the absolute peripheral blood monocyte count does not reach a diagnostic level bu...
Source: Best Practice and Research Clinical Haematology - December 15, 2019 Category: Hematology Source Type: research

Moving towards a uniform risk stratification system in CMML - how far are we?
Publication date: Available online 6 December 2019Source: Best Practice & Research Clinical HaematologyAuthor(s): Onyee Chan, Eric PadronAbstractMany prognostic scoring systems have been developed for chronic myelomonocytic leukemia (CMML). Although these efforts have been informative, no single model has been considered the consensus for CMML prognostication and all models are only moderately prognostic. CMML clinical models utilize mainly hematology and morphology parameters to estimate risk. A better understanding of cytogenetics and the genomic landscape of CMML have resulted in integrated risk models such as CMML ...
Source: Best Practice and Research Clinical Haematology - December 8, 2019 Category: Hematology Source Type: research

Atypical CML-the Role of Morphology and Precision Genomics
Publication date: Available online 6 December 2019Source: Best Practice & Research Clinical HaematologyAuthor(s): Terra LashoAbstractAtypical chronic myeloid leukemia is an esoteric myeloid malignancy with features of both myeloproliferative and myelodysplastic syndromes. This disease is characterized primarily by morphologic-based criteria, and has clinical and molecular features overlapping with other myeloid malignancies. No one molecular abnormality is specific, and multiple mutations are often present in various combinations, due to the malignant multi-step clonal evolution of myeloid malignancies. In this review,...
Source: Best Practice and Research Clinical Haematology - December 8, 2019 Category: Hematology Source Type: research

Myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): More than just a “catch-all” term?
Publication date: Available online 6 December 2019Source: Best Practice & Research Clinical HaematologyAuthor(s): Rory M. Shallis, Amer M. ZeidanAbstractThe clinicopathology of MDS and MPN are not mutually exclusive and for this reason the category of myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) exists. Several sub-entities have been included under the MDS/MPN umbrella, including MDS/MPN-unclassifiable (MDS/MPN-U) for those cases whose morphologic and clinical phenotype do not meet criteria to be classified as any other MDS/MPN sub-entity. Though potentially regarded as a wastebasket diagnosis, since ...
Source: Best Practice and Research Clinical Haematology - December 8, 2019 Category: Hematology Source Type: research

Myelodysplastic/Myeloproliferative neoplasms – justified inclusion as unique biological entities
Publication date: Available online 7 December 2019Source: Best Practice & Research Clinical HaematologyAuthor(s): Mrinal M. Patnaik (Source: Best Practice and Research Clinical Haematology)
Source: Best Practice and Research Clinical Haematology - December 8, 2019 Category: Hematology Source Type: research

Incorporating flow cytometry and next-generation sequencing in the diagnosis of CMML. Are we ready for prime?
Publication date: Available online 7 December 2019Source: Best Practice & Research Clinical HaematologyAuthor(s): Eric Solary, Orianne Wagner-Ballon, Dorothée Selimoglu-BuetAbstractIn the last version of the WHO classification of myeloid malignancies, flow cytometry and molecular investigation are listed as potentially useful, yet non-essential diagnostic tools in hard-to-recognize chronic myelomonocytic leukemias (CMML). Flow recognition of CMML was initially based on an increase in the fraction of peripheral blood, CD14+,CD16- classical monocytes ≥ 94% of total monocytes. An associated inflammatory disease ...
Source: Best Practice and Research Clinical Haematology - December 8, 2019 Category: Hematology Source Type: research

Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes – Advances in Treatment
Publication date: Available online 3 December 2019Source: Best Practice & Research Clinical HaematologyAuthor(s): Kristen B. McCullough, Mrinal M. PatnaikAbstractOptimal treatment for myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes remain to be defined and are currently extrapolated from MDS and MPN. The heterogeneity of these diseases and their rare occurrences add to this void. Supportive care therapies such as erythropoiesis stimulating agents, iron chelation and cytoreductive therapy do not have prospective evidence in these disorders and the only approved treatments, hypomethylatin...
Source: Best Practice and Research Clinical Haematology - December 5, 2019 Category: Hematology Source Type: research

Editorial Board / Aims & Scope
Publication date: December 2019Source: Best Practice & Research Clinical Haematology, Volume 32, Issue 4Author(s): (Source: Best Practice and Research Clinical Haematology)
Source: Best Practice and Research Clinical Haematology - November 26, 2019 Category: Hematology Source Type: research

Index
Publication date: December 2019Source: Best Practice & Research Clinical Haematology, Volume 32, Issue 4Author(s): (Source: Best Practice and Research Clinical Haematology)
Source: Best Practice and Research Clinical Haematology - November 26, 2019 Category: Hematology Source Type: research

Introducing article numbering to Best Practice & Research Clinical Haematology
Publication date: Available online 2 November 2019Source: Best Practice & Research Clinical HaematologyAuthor(s): (Source: Best Practice and Research Clinical Haematology)
Source: Best Practice and Research Clinical Haematology - November 4, 2019 Category: Hematology Source Type: research

What is the role of the microenvironment in MDS?
Publication date: Available online 28 October 2019Source: Best Practice & Research Clinical HaematologyAuthor(s): Laura M. Calvi, Allison J. Li, Michael W. BeckerAbstractTreating myelodysplastic syndromes (MDS) can be complex. Hematopoiesis occurs within a heterogeneous and complex dynamic microenvironment, and a multiplicity of mutations in hematopoietic stem and progenitor cells (HSPCs) lead to MDS. But is there a role for the microenvironment? Here we review experimental and conceptual arguments that support a role for the microenvironment, provide evidence for the disruption of the microenvironment in MDS, and expl...
Source: Best Practice and Research Clinical Haematology - October 29, 2019 Category: Hematology Source Type: research

Which novel agents hold the greatest promise in AML?
Publication date: Available online 18 October 2019Source: Best Practice & Research Clinical HaematologyAuthor(s): Courtney D. DiNardoAbstractThe therapeutic landscape for acute myeloid leukemia (AML) has changed dramatically with the approval of targeted agents, including venetoclax, midostaurin, gilteritinib, ivosidenib, and enasidenib, among others. However, older patients with AML continue to experience poorer outcomes and are in ongoing need of more effective and less toxic regimens. This review examines the efficacy of novel therapeutics and promising combination approaches to further improve outcomes in the treat...
Source: Best Practice and Research Clinical Haematology - October 26, 2019 Category: Hematology Source Type: research

Is post-transplant cyclophosphamide a true game-changer in allogeneic transplantation: the struggle to unlearn
Publication date: Available online 20 October 2019Source: Best Practice & Research Clinical HaematologyAuthor(s): Richard J. JonesAbstractClose HLA matching of donors and recipients has been the dogma for successful allogeneic blood or marrow transplantation (BMT), to limit the complications of graft rejection and graft-versus-host disease (GVHD). However, many patients in need, especially those in certain racial and ethnic groups such as African-Americans and Hispanics, are unable to find matches despite increased availability of unrelated donors. Unfortunately, despite many early attempts to develop safe, related hap...
Source: Best Practice and Research Clinical Haematology - October 21, 2019 Category: Hematology Source Type: research

Acute myeloid leukemia: How to treat the fit patient over age 75?
Publication date: Available online 19 October 2019Source: Best Practice & Research Clinical HaematologyAuthor(s): Selina LugerAbstractSurvival rates for patients with acute myeloid leukemia (AML) older than 75 years are still quite dismal. Recent approvals, therefore, of two agents specifically to treat older patients—glasdegib and venetoclax—have created excitement among the medical community. Clinical data, particularly complete response (CR) rates and CR with incomplete hematologic recovery (CRi), look quite promising and are reviewed here. Yet the question remains whether fit elderly patients should rec...
Source: Best Practice and Research Clinical Haematology - October 20, 2019 Category: Hematology Source Type: research

Beyond midostaurin: Which are the most promising FLT3 inhibitors in AML?
Publication date: Available online 18 October 2019Source: Best Practice & Research Clinical HaematologyAuthor(s): Eunice S. WangAbstractMutations of FLT3 occur in around a third of acute myeloid leukemia (AML) patients and are associated with poor outcomes. Multiple targeted tyrosine kinase inhibitors (TKI) have been developed with different selectivity and potency for FLT3 mutant clones. Indications for which FLT3-inhibitor to use depend on the clinical setting and disease status. Patients with relapsed or refractory AML benefit from a different TKI than those with de novo AML or following stem cell transplant. Moreov...
Source: Best Practice and Research Clinical Haematology - October 20, 2019 Category: Hematology Source Type: research

Post-remission therapy in acute myeloid leukemia: Are we ready for an individualized approach?
Publication date: Available online 18 October 2019Source: Best Practice & Research Clinical HaematologyAuthor(s): Benjamin A. Derman, Richard A. LarsonAbstractRecent advances in remission induction treatment strategies for acute myeloid leukemia (AML) have improved the rates of complete remission (CR) and overall survival (OS), owing to a concerted effort to tailor therapies toward specific AML subtypes. However, without effective post-remission therapy, most patients will relapse. The extent to which post-remission therapies is individualized in the current paradigm is quite varied. Core binding factor (CBF) AML is ty...
Source: Best Practice and Research Clinical Haematology - October 18, 2019 Category: Hematology Source Type: research